Hong Kong-listed Everest Medicines Limited is mulling tweaking its business strategy of in-licensing Asia territory rights to foreign drug candidates, with a potential focus on renal diseases taking the front seat.
The Chinese biotech’s tentative departure from the crowded therapeutic area of oncology surfaced after it sold back to Gilead...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?